［1］ ZHENG RS,CHEN R,HAN BF,et al.Cancer incidence and mortality in China,2022［J］.Chinese Journal of Oncology,2024，46（3）：221-231.
［2］ BRAY F,LANERSANNEW M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin,2024，74（3）：229-263.
［3］ TRUXOVA I,CIBULA D,SPISEK R,et al.Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma［J］.J ImmunoTher Cancer,2023,11（2）:e005968.
［4］ MARCUS L,LEMERY SJ,KEEGAN P,et al.FDA approval summary:pembrolizumab for the treatment of microsatellite instability-high solid tumors［J］.Clin Cancer Res,2019,25（13）:3753-3758.
［5］ KUDO M,FINN RS,QIN S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial［J］.Lancet,2018,391（10126）:1163-1173.
［6］ VERGOTE I,POWELL MA,TENERIELLO MG,et al.Second-line lenvatinib in patients with recurrent endometrial cancer［J］.Gynecol Oncol,2020,156（3）:575-582.
［7］ TAYLOR MH,SCHMIDT EV,DUTCUS C,et al.The LEAP program:lenvatinib plus pembrolizumab for the treatment of advanced solid tumors［J］.Future Oncol,2021,17（6）:637-648.
［8］ ZAK KM,KITEL R,PRZETOCKA S,et al.Structure of the complex of human programmed death 1,PD-1,and its ligand PD-L1［J］.Structure,2015,23（12）:2341-2348.
［9］ HUI E,CHEUNG J,ZHU J,et al.T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition［J］.Science,2017,355（6332）:1428-1433.
［10］ BOUSSIOTIS VA.Molecular and biochemical aspects of the PD-1 checkpoint pathway［J］.N Engl J Med,2016,375（18）:1767-1778.
［11］ PATSOUKIS N,BROWN J,PETKOVA V,et al.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation［J］.Sci Signal,2012,5（230）:ra46.
［12］ BAGCHI S,YUAN R,ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance［J］.Annu Rev Pathol,2021,16：223-249.
［13］ SUYAMA K,IWASE H.Lenvatinib:a promising molecular targeted agent for multiple cancers［J］.Cancer Control,2018,25（1）:1073274818789361.
［14］ ZHAO Y,ZHANG YN,WANG KT,et al.Lenvatinib for hepatocellular carcinoma:from preclinical mechanisms to anti-cancer therapy［J］.Biochim Biophys Acta Rev Cancer,2020,1874（1）:188391.
［15］ KATO Y,TABATA K,KIMURA T,et al.Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+T cells through reduction of tumor-associated macrophage and activation of the interferon pathway［J］.PLoS One,2019,14（2）:e0212513.
［16］ NAIR A,LEMERY SJ,YANG J,et al.FDA approval summary:lenvatinib for progressive,radio-iodine-refractory differentiated thyroid cancer［J］.Clin Cancer Res,2015,21（23）:5205-5208.
［17］ KANDALAFT LE,MOTZ GT,BUSCH J,et al.Angiogenesis and the tumor vasculature as antitumor immune modulators:the role of vascular endothelial growth factor and endothelin［J］.Curr Top Microbiol Immunol,2011,344：129-148.
［18］ RAMJIAWAN RR,GRIFFIOEN AW,DUDA DG.Anti-angiogenesis for cancer revisited:is there a role for combinations with immunotherapy［J］.Angiogenesis,2017,20（2）:185-204.
［19］ UNE N,TAKANO-KASUYA M,KITAMURA N,et al.The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors［J］.Med Oncol,2021,38（6）:60.
［20］ JAIN RK.Antiangiogenesis strategies revisited:from starving tumors to alleviating hypoxia［J］.Cancer Cell,2014,26（5）:605-622.
［21］ RIVERA LB,MEYRONET D,HERVIEU V,et al.Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy［J］.Cell Rep,2015,11（4）:577-591.
［22］ SCHMITTNAEGEL M,RIGAMONTI N,KADIOGLU E,et al.Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade［J］.Sci Transl Med,2017,9（385）:eaak9670.
［23］ ALLEN E,JABOUILLE A,RIVERA LB,et al.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation［J］.Sci Transl Med,2017,9（385）:eaak9679.
［24］ TAYLOR MH,LEE CH,MAKKER V,et al.Phase Ⅰb/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma,endometrial cancer,and other selected advanced solid tumors［J］.J Clin Oncol,2020,38（11）:1154-1163.
［25］ MAKKER V,RASCO D,VOGELZANG NJ,et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer:an interim analysis of a multicentre,open-label,single-arm,phase 2 trial［J］.Lancet Oncol,2019,20（5）:711-718.
［26］ MAKKER V,TAYLOR MH,AGHAJANIAN C,et al.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer［J］.J Clin Oncol,2020,38（26）:2981-2992.
［27］ MAKKER V,AGHAJANIAN C,COHN AL,et al.A phase Ⅰb/Ⅱ study of lenvatinib and pembrolizumab in advanced endometrial carcinoma（Study 111/KEYNOTE-146）:long-term efficacy and safety update［J］.J Clin Oncol,2023,41（5）:974-979.
［28］ MOTZER RJ,HUTSON TE,GLEN H,et al.Lenvatinib,everolimus,and the combination in patients with metastatic renal cell carcinoma:a randomised,phase 2,open-label,multicentre trial［J］.Lancet Oncol,2015,16（15）:1473-1482.
［29］ O' MALLEY DM,BARIANI GM,CASSIER PA,et al.Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer:results from the KEYNOTE-158 study［J］.J Clin Oncol,2022,40（7）:752-761.
［30］ MAKKER V,COLOMBO N,CASADO HERRAEZ A,et al.Lenvatinib plus pembrolizumab for advanced endometrial cancer［J］.N Engl J Med,2022,386（5）:437-448.
［31］ YONEMORI K,YUNOKAWA M,USHIJIMA K,et al.Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer:results from study 309/KEYNOTE-775［J］.Cancer Sci,2022,113（10）:3489-3497.
［32］ MARTH C,TARNAWSKI R,TYULYANDINA A,et al.Phase 3,randomized,open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer:ENGOT-en9/LEAP-001［J］.Int J Gynecol Cancer,2022,32（1）:93-100.
［33］ ARANCE A,DE LA CRUZ-MERINO L,PETRELLA TM,et al.Phase Ⅱ LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination［J］.J Clin Oncol,2023,41（1）:75-85.
［34］ HUANG Y,YUAN J,RIGHI E,et al.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy［J］.Proc Natl Acad Sci USA,2012,109（43）:17561-17566.